Bioxcel therapeutics announces positive top-line data from repeat dosing of bxcl501 in phase 1b multiple ascending dose trial in healthy volunteers for major depressive disorder (mdd) program

Bxcl501 was well tolerated across a broad dose range from 30mcg to 140mcg administered chronically  planning phase 2 human proof-of-concept study to evaluate bxcl501 as a potential adjunctive treatment in mdd data further supportive of ongoing clinical programs evaluating bxcl501 for potential at-home use for agitation associated with schizophrenia or bipolar disorders (serenity iii) and agitation associated with alzheimer's disease (tranquility ii and iii) new haven, conn., may 16, 2023 (globe newswire) -- bioxcel therapeutics, inc. (nasdaq: btai), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced positive top-line data from its phase 1b multiple ascending dose (mad) trial of bxcl501 (dexmedetomidine) sublingual film.
BTAI Ratings Summary
BTAI Quant Ranking